HTBX - Heat Biologics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.6069
-0.0431 (-6.63%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close0.6500
Open0.6500
Bid0.6001 x 1000
Ask0.6030 x 2900
Day's Range0.6000 - 0.6500
52 Week Range0.6000 - 2.2400
Volume192,132
Avg. Volume299,612
Market Cap20.674M
Beta (3Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • What You Must Know About Heat Biologics, Inc.'s (NASDAQ:HTBX) Beta Value
    Simply Wall St.11 days ago

    What You Must Know About Heat Biologics, Inc.'s (NASDAQ:HTBX) Beta Value

    If you own shares in Heat Biologics, Inc. (NASDAQ:HTBX) then it's worth thinking about how it contributes to the...

  • Zacks Small Cap Researchlast month

    HTBX: INDs To Be Filed Soon

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT First Quarter 2019 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported first quarter 2019 results in a May 15 release and concurrently ...

  • Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers?
    Simply Wall St.2 months ago

    Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers?

    Jeff Wolf has been the CEO of Heat Biologics, Inc. (NASDAQ:HTBX) since 2008. This analysis aims first to contrast CEO...

  • Zacks Small Cap Research3 months ago

    HTBX: 2018 Financial & Operational Results

    By John Vandermosten, CFA NASDAQ:HTBX READ THE LATEST HTBX RESEARCH REPORT Full Year 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported full year 2018 results in a March 28 release and concurrently ...

  • Zacks Small Cap Research4 months ago

    HTBX: HS-110 Interim Update

    By John Vandermosten, CFA NASDAQ:HTBX Heat Biologics, Inc. (NASDAQ:HTBX) has continued to progress in their HS-110 Durga trial, recently providing interim results at the ASCO-SITC Clinical Immuno-Oncology ...

  • What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?
    Simply Wall St.5 months ago

    What Type Of Shareholder Owns Heat Biologics, Inc.’s (NASDAQ:HTBX)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Heat Biologics, Inc. (NASDAQ:HTBX)Read More...

  • Benzinga6 months ago

    The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9:  China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...

  • Zacks Small Cap Research8 months ago

    HTBX: Plenty of Catalysts in 2019

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Third Quarter 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported third quarter 2018 results in an August 14th release and ...

  • Durham company rakes in another $13.8M through public offering
    American City Business Journals8 months ago

    Durham company rakes in another $13.8M through public offering

    Heat Biologics just banked an additional $13.8 million in its latest public offering. The Durham-based biopharmaceutical company (Nasdaq: HTBX) announced the public offering last week. It estimated the gross proceeds from the offering to come close to $12 million. At close on Monday, that figure realized an additional $1.8 million.

  • TheStreet.com8 months ago

    Heat Biologics Takes Beating After Pricing $12 Million Stock Offering

    The North Carolina-based biopharmaceutical company expected to offer 8 million shares of common stock and warrants to purchase 4 million shares of common stock with an expected combined price of $1.50. The money raised would be used to further develop its so-called T-cell immunotherapies that if successful would activate a patient's immune system to fight off cancer. , a London-based clinical-stage biopharmaceutical company, slipped 1.76% to $7.82, while New York-based Axsome Therapeutics, Inc.

  • Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Historical Volatility?
    Simply Wall St.8 months ago

    Should You Be Concerned About Heat Biologics Inc’s (NASDAQ:HTBX) Historical Volatility?

    If you own shares in Heat Biologics Inc (NASDAQ:HTBX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

  • Benzinga8 months ago

    The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 20) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX Down In ...

  • Simply Wall St.10 months ago

    What does Heat Biologics Inc’s (NASDAQ:HTBX) Balance Sheet Tell Us About Its Future?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Heat Biologics Inc (NASDAQ:HTBX), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...

  • Zacks Small Cap Research11 months ago

    HTBX: Multiple Milestones on the Horizon

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Second Quarter 2018 Results Heat Biologics, Inc. (NASDAQ:HTBX) reported second quarter 2018 results in an August 14th release and ...

  • InvestorPlace11 months ago

    Heat Biologics Stock Is a Worthwhile, Speculative Bet

    Investors still waiting for Heat Biologics (NASDAQ:HTBX) to trade at a market cap of $100 million will have to wait longer. The biotechnology company, whose market capitalization is just $43 million, which puts it in the nano-cap territory, does not have much to offer except for hope. On May 3, HTBX stock slumped by around 50% when the company filed a preliminary prospectus for the public sale of nearly 4.3 million shares.